BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 11830491)

  • 1. Regulation of the Erk2-Elk1 signaling pathway and megakaryocytic differentiation of Bcr-Abl(+) K562 leukemic cells by Gab2.
    Dorsey JF; Cunnick JM; Mane SM; Wu J
    Blood; 2002 Feb; 99(4):1388-97. PubMed ID: 11830491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
    Gu S; Chan WW; Mohi G; Rosenbaum J; Sayad A; Lu Z; Virtanen C; Li S; Neel BG; Van Etten RA
    Blood; 2016 Apr; 127(14):1803-13. PubMed ID: 26773044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protein tyrosine phosphatase HePTP regulates nuclear translocation of ERK2 and can modulate megakaryocytic differentiation of K562 cells.
    Pettiford SM; Herbst R
    Leukemia; 2003 Feb; 17(2):366-78. PubMed ID: 12592337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical role for Gab2 in transformation by BCR/ABL.
    Sattler M; Mohi MG; Pride YB; Quinnan LR; Malouf NA; Podar K; Gesbert F; Iwasaki H; Li S; Van Etten RA; Gu H; Griffin JD; Neel BG
    Cancer Cell; 2002 Jun; 1(5):479-92. PubMed ID: 12124177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
    Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
    Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Participation of both Gab1 and Gab2 in the activation of the ERK/MAPK pathway by epidermal growth factor.
    Meng S; Chen Z; Munoz-Antonia T; Wu J
    Biochem J; 2005 Oct; 391(Pt 1):143-51. PubMed ID: 15952937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
    Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
    J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of the tyrosine phosphatase SHP-2 with Gab2 regulates Rho-dependent activation of the c-fos serum response element by interleukin-2.
    Arnaud M; Mzali R; Gesbert F; Crouin C; Guenzi C; Vermot-Desroches C; Wijdenes J; Courtois G; Bernard O; Bertoglio J
    Biochem J; 2004 Sep; 382(Pt 2):545-56. PubMed ID: 15170389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nobiletin Promotes Megakaryocytic Differentiation through the MAPK/ERK-Dependent EGR1 Expression and Exerts Anti-Leukemic Effects in Human Chronic Myeloid Leukemia (CML) K562 Cells.
    Yen JH; Lin CY; Chuang CH; Chin HK; Wu MJ; Chen PY
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gab2, a new pleckstrin homology domain-containing adapter protein, acts to uncouple signaling from ERK kinase to Elk-1.
    Zhao C; Yu DH; Shen R; Feng GS
    J Biol Chem; 1999 Jul; 274(28):19649-54. PubMed ID: 10391903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphoinositide 3-kinase-dependent regulation of interleukin-3-induced proliferation: involvement of mitogen-activated protein kinases, SHP2 and Gab2.
    Craddock BL; Hobbs J; Edmead CE; Welham MJ
    J Biol Chem; 2001 Jun; 276(26):24274-83. PubMed ID: 11335710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
    Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
    Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcr-Abl regulates protein kinase Ciota (PKCiota) transcription via an Elk1 site in the PKCiota promoter.
    Gustafson WC; Ray S; Jamieson L; Thompson EA; Brasier AR; Fields AP
    J Biol Chem; 2004 Mar; 279(10):9400-8. PubMed ID: 14670960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. G-CSF-induced tyrosine phosphorylation of Gab2 is Lyn kinase dependent and associated with enhanced Akt and differentiative, not proliferative, responses.
    Zhu QS; Robinson LJ; Roginskaya V; Corey SJ
    Blood; 2004 May; 103(9):3305-12. PubMed ID: 14656892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling.
    Li S; Couvillon AD; Brasher BB; Van Etten RA
    EMBO J; 2001 Dec; 20(23):6793-804. PubMed ID: 11726515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.
    Chang JS; Santhanam R; Trotta R; Neviani P; Eiring AM; Briercheck E; Ronchetti M; Roy DC; Calabretta B; Caligiuri MA; Perrotti D
    Blood; 2007 Aug; 110(3):994-1003. PubMed ID: 17475908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.
    Horita M; Andreu EJ; Benito A; Arbona C; Sanz C; Benet I; Prosper F; Fernandez-Luna JL
    J Exp Med; 2000 Mar; 191(6):977-84. PubMed ID: 10727459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
    Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.